Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Analysis of COVID-19 patient outcomes with molnupiravir treatment and the role of risk factors: a single-centre retrospective descriptive study

O. Zahornacký, Š. Porubčin, A. Rovňáková, P. Jarčuška, D. Semenovová, P. Kubalcová, E. Dorko, K. Rimárová

. 2024 ; 32 (Suppl.) : 104-110. [pub] -

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25006810

Digitální knihovna NLK
Zdroj

E-zdroje Online Plný text

NLK Free Medical Journals od 2004
ProQuest Central od 2009-03-01 do Před 6 měsíci
Medline Complete (EBSCOhost) od 2006-03-01 do Před 6 měsíci
Nursing & Allied Health Database (ProQuest) od 2009-03-01 do Před 6 měsíci
Health & Medicine (ProQuest) od 2009-03-01 do Před 6 měsíci
Public Health Database (ProQuest) od 2009-03-01 do Před 6 měsíci
ROAD: Directory of Open Access Scholarly Resources od 1993

OBJECTIVE: This study aims to describe the outcomes of COVID-19 patients treated with molnupiravir and to explore the associations with various risk factors. METHODS: We conducted a single-centre, descriptive, retrospective study without a comparison group. RESULTS: Out of 141 patients, 70 (49.7%) required follow-up outpatient care. In the subgroup of 66 (46.8%) hospitalized patients, 28 (19.9%) developed interstitial viral pneumonia, with 6 (4.3%) deaths. Unvaccinated patients had a higher incidence of pneumonia (p = 0.020), and obesity was a significant risk factor for both pneumonia (p = 0.001) and mortality (p = 0.011). Patients over 60 years (p = 0.040) and those with cardiovascular diseases (p = 0.026) also had increased pneumonia risk. Male sex was associated with a higher risk of death (p = 0.020). CONCLUSION: Molnupiravir treatment was linked to reduced risks of hospitalization and death, particularly in high-risk patients. Vaccination provided additional protection, and obesity obstructive pulmonary disease and autoimmune diseases were significant risk factors for severe outcomes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25006810
003      
CZ-PrNML
005      
20250403105209.0
007      
ta
008      
250311s2024 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.21101/cejph.a8398 $2 doi
035    __
$a (PubMed)39832155
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Zahornacký, Ondrej $u Department of Infectology and Travel Medicine, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic $7 xx0241911
245    10
$a Analysis of COVID-19 patient outcomes with molnupiravir treatment and the role of risk factors: a single-centre retrospective descriptive study / $c O. Zahornacký, Š. Porubčin, A. Rovňáková, P. Jarčuška, D. Semenovová, P. Kubalcová, E. Dorko, K. Rimárová
520    9_
$a OBJECTIVE: This study aims to describe the outcomes of COVID-19 patients treated with molnupiravir and to explore the associations with various risk factors. METHODS: We conducted a single-centre, descriptive, retrospective study without a comparison group. RESULTS: Out of 141 patients, 70 (49.7%) required follow-up outpatient care. In the subgroup of 66 (46.8%) hospitalized patients, 28 (19.9%) developed interstitial viral pneumonia, with 6 (4.3%) deaths. Unvaccinated patients had a higher incidence of pneumonia (p = 0.020), and obesity was a significant risk factor for both pneumonia (p = 0.001) and mortality (p = 0.011). Patients over 60 years (p = 0.040) and those with cardiovascular diseases (p = 0.026) also had increased pneumonia risk. Male sex was associated with a higher risk of death (p = 0.020). CONCLUSION: Molnupiravir treatment was linked to reduced risks of hospitalization and death, particularly in high-risk patients. Vaccination provided additional protection, and obesity obstructive pulmonary disease and autoimmune diseases were significant risk factors for severe outcomes.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a rizikové faktory $7 D012307
650    12
$a farmakoterapie COVID-19 $7 D000093485
650    12
$a antivirové látky $x terapeutické užití $7 D000998
650    _2
$a senioři $7 D000368
650    12
$a cytidin $x analogy a deriváty $x terapeutické užití $7 D003562
650    _2
$a hydroxylaminy $x terapeutické užití $7 D006898
650    _2
$a COVID-19 $x mortalita $x epidemiologie $7 D000086382
650    _2
$a SARS-CoV-2 $7 D000086402
650    _2
$a dospělí $7 D000328
650    _2
$a výsledek terapie $7 D016896
650    _2
$a hospitalizace $x statistika a číselné údaje $7 D006760
650    _2
$a leucin $x terapeutické užití $x analogy a deriváty $7 D007930
655    _2
$a časopisecké články $7 D016428
700    1_
$a Porubčín, Štefan $u Department of Infectology and Travel Medicine, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic $7 _AN122180
700    1_
$a Rovňáková, Alena $u Department of Infectology and Travel Medicine, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic $7 xx0241883
700    1_
$a Jarčuška, Pavol $u Department of Infectology and Travel Medicine, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic $7 xx0073933
700    1_
$a Semenovová, Dária $u Department of Infectology and Travel Medicine, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic $7 _AN122181
700    1_
$a Kubalcová, Paulína $u Department of Radiology, AGEL Hospital, Levoca, Slovak Republic $7 _AN122099
700    1_
$a Dorko, Erik $u Department of Public Health and Hygiene, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic $7 xx0063738
700    1_
$a Rimárová, Kvetoslava, $u Department of Public Health and Hygiene, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic $d 1958- $7 xx0224806
773    0_
$w MED00001083 $t Central European journal of public health $x 1210-7778 $g Roč. 32, Suppl. (2024), s. 104-110
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39832155 $y Pubmed
910    __
$a ABA008 $b B 1829 $c 562 $y p $z 0
990    __
$a 20250311 $b ABA008
991    __
$a 20250403105204 $b ABA008
999    __
$a ok $b bmc $g 2295224 $s 1243875
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 32 $c Suppl. $d 104-110 $e - $i 1210-7778 $m Central European journal of public health $n Cent Eur J Public Health $x MED00001083
LZP    __
$b NLK116 $a Pubmed-20250311

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...